Evidence item

The reservoir decline was measured in 22 antibody-arm participants at a mean of 52 weeks, and only intact—not defective—proviruses declined. MEASUREMENT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 25318

Source: Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial · locator {} · excerpt hash sha256:fe2d12000ec9e7c65952d7cdd33f893f506ac5338b76768a4af4fed8e9480f4e

Exact excerpt

To determine how the bNAbs impact the size of the proviral reservoir in arm A, we compared the intact and defective proviral reservoirs at baseline with prerebound samples collected at a mean of 52 weeks after the initial infusion (n = 22; Fig. 6 and Supplementary Table 1). ... Although there was a great deal of variation between individuals in arm A over time, the intact reservoir but not the defective one was significantly smaller after bNAb therapy with an estimated half-life of 36 weeks (n = 22).

Linked claims

Claim	Direction	Relevance	Steps	Counted
1304f296	QUALIFY	DIRECT	0	yes

Audits

None.